Biopharma and med-tech company deals and M&As: Abbott, Alvotech, Ambros, Amplitude, Avricore, Beyond Air, Bioarctic, BMS, Chai Discovery, Chong Kun Dang, Darmiyan ...

Remedium Bio Inc. has announced the initial closing of its planned $10 million series A financing as it advances its durable protein therapeutics platform toward first-in-human development.

A compound targeting serotonin receptor 5-HT2A (5-HT2AR) signaling in the gut could activate antitumor immunity in colorectal cancer (CRC) and improve responses to immunotherapy without causing ...

Innovstone Therapeutics Ltd. has synthesized cathepsin C (dipeptidyl peptidase I; DPP-1) inhibitors found to be potentially useful for the treatment of autoimmune diseases and cancer.

An increase in the level of M&A activity and some sizeable financing rounds are encouraging signs for the med-tech investment environment, said Joey Mason, life sciences venture partner at Claret ...

At the Alzheimer’s Association International Conference, researchers from Voyager Therapeutics Inc. presented preclinical efficacy data for VY-1706, a blood-brain barrier-penetrant AAV9 gene therapy ...

New research has teased out specific aspects of how Epstein-Barr virus (EBV) sparks the immune response that leads on to the development of multiple sclerosis (MS), opening the way to the rational ...

BioWorld - Sunday, August 30, 2026 Breaking News: Best of BioWorld Science: Q2 See today's BioWorld Science Home » BioWorld Science » Nampt inhibitors reported in Alphina Therapeutics patent To read ...

Takeda Pharmaceutical Co. Ltd.’s anti-CD38 antibody mezagitamab (TAK-079) is showing benefits beyond platelet restoration, with new data suggesting the candidate may improve quality of life for ...

Researchers from Connecta Therapeutics SL and the Centre for Genomic Regulation (Barcelona Institute of Science and Technology) recently presented preclinical results on CTH-120, a potential ...

Researchers from Stony Brook University Renaissance School of Medicine recently disclosed the design and development of a novel, multitargeted miRNA approach based on a gemcitabine-modified microRNA ...

Eli Lilly and Co. posted $19.8 billion in first-quarter 2026 revenue, driven by tirzepatide, marketed as Mounjaro for type 2 diabetes and Zepbound for obesity. The Indianapolis-based drugmaker is ...